Australia's Imugene tops the ASX 200, at an over four-month high

Imugene

10/08/2022 03:36

** Shares of Imugene  IMU.AX  soar as much as nearly 13% to
A$0.305, topping the benchmark ASX 200
    ** Cancer-focused biopharma co hits its highest since March
24
    ** Co says City of Hope, cancer research and treatment
organisation in United States, dosed first patient in Cohort 3
in the Phase I clinical trial of CHECKvacc, an oncolytic
virotherapy candidate urn:newsml:reuters.com:*:nASX2694Qt
    ** Co says in cohort 1 and 2 of the trial they saw positive
results in oncolytic virus infection and replication in the
triple negative breast cancer tumours and there remains no
observed toxicity
    ** Stock is down 32.5% this year, as of last close 
    


 (Reporting by Navya Mittal in Bengaluru)
 ((navya.mittal@thomsonreuters.com))